Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival-Reference-Cited by-同舟云学术

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

Published:2012-12-25 Issue:4 Volume:16 Page:581-589
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Kang Eun Joo,Im Seock-Ah,Oh Do-Youn,Han Sae-Won,Kim Jin-Soo,Choi In Sil,Kim Jin Won,Kim Yu Jung,Kim Jee Hyun,Kim Tae-You,Lee Jong Seok,Bang Yung-Jue,Lee Keun-Wook

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-012-0227-5.pdf

Reference28 articles.

1. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011;43(1):1–11. doi: 10.4143/crt.2011.43.1.1 .

2. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27(5):812–26. doi: 10.1200/JCO.2008.21.2134 .

3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9. doi: 10.1200/JCO.2005.05.0245 .

4. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.

5. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14. doi: 10.1016/j.ejca.2011.06.002 .